Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer
- 17 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 185 (1), 73-84
- https://doi.org/10.1007/s10549-020-05927-5
Abstract
Purpose Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor survival outcomes. Metformin has been shown to have antitumor effects by lowering serum levels of the mitogen insulin and having pleiotropic effects on cancer cell signaling pathways. BMS-754807 is a potent and reversible inhibitor of both insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR). Both drugs have been reported to have some efficacy in TNBC. However, it is unclear whether the combination of the two drugs is more effective than single drug treatment in TNBC. Methods We treated a panel of TNBC cell lines with metformin and BMS-754807 alone and in combination and tested cell viability using MTS assays. We used the CompuSyn software to analyze for additivity, synergism, or antagonism. We also examined the molecular mechanism by performing reverse phase protein assay (RPPA) to detect the candidate pathways altered by single drugs and the drug combination and used Western blotting to verify and expand the findings. Results The combination of metformin and BMS-754807 showed synergy in 11 out of 13 TNBC cell lines tested (85%). RPPA analysis detected significant alterations by the drug combination of multiple proteins known to regulate cell cycle and tumor growth. In particular, the drug combination significantly increased levels of total and phosphorylated forms of the cell cycle inhibitor p27Kip1 and decreased the level of the p27Kip1 E3 ligase SCFSkp2. Conclusions We conclude that the combination of metformin and BMS-754807 is more effective than either drug alone in inhibiting cell proliferation in the majority of TNBC cell lines, and that one important mechanism may be suppression of SCFSkp2 and subsequent stabilization of the cell cycle inhibitor p27Kip1. This combination treatment may represent an effective targeted therapy for a significant subset of TNBC cases and should be further evaluated.Keywords
Funding Information
- Foundation for the National Institutes of Health (R01CA204926, P50CA186784 Project 3)
- Cancer Prevention & Research Institute of Texas Proteomics & Metabolomics Core Facility Support Award (RP170005)
- NCI Cancer Center Support Grant to Antibody-based Proteomics Core/Shared Resource (P30CA125123)
- Chinese Scholarship Council (CSC) scholarship (201406860002)
- Susan G. Komen Foundation (CCR13263802)
This publication has 68 references indexed in Scilit:
- Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast CancerPLOS ONE, 2013
- Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival PathwaysPLOS ONE, 2012
- Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical TrialJournal of Clinical Oncology, 2012
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancerCancer, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR TherapyClinical Cancer Research, 2011
- Diabetes and CancerDiabetes Care, 2010
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2Cell, 2007